For the treatment of primary immunodeficiency (PI) in patients 2 years of age and older
Maximum infusion rate 14 mg/kg/min, as tolerated; absences from work or school=3.6 days/person-year.
Not actual patient.
Is PI part of your story?
Ask your doctor about proven results with PANZYGA
PANZYGA is an FDA-approved treatment that offers patients infusion speed along with a proven efficacy and safety track record.
Explore these helpful topics to see if PANZYGA can help you on your journey with PI.
*Eligible, commercially insured patients may receive a maximum benefit of $12,500 per year or the cost of a patient’s co-pay in a 12-month period (whichever is less) for claims received by the program. No membership fees are required. Federal and state healthcare beneficiaries are not eligible. The PANZYGA Co-Pay Program is good only in the US and Puerto Rico. Terms and conditions/eligibility requirements apply. See full Terms and Conditions on the Financial assistance programs page.
Want support talking to your doctor about PANZYGA?
Download this helpful guide with questions that you can bring to your next appointment
